11.54

14.42% -1.945

Sellas Life Sciences Group Inc (SLS)

Overview News Price History Option Chain Financials Why SLS Down? Discussions Forecast Stock Split

Sellas Life Sciences Group Inc stock is traded at $11.54, with a volume of 14.56M. It is down -14.42% in the last 24 hours and up +4.48% over the past month. SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Previous Close:

$13.49

Open:

$13.55

24h Volume:

14.56M

Relative Volume:

1.78

Market Cap:

$2.33B

Revenue:

Net Income/Loss:

$-29.46M

P/E Ratio:

-50.57

EPS:

-0.2283

Net Cash Flow:

$-28.17M

1W Performance:

-16.70%

1M Performance:

+4.48%

6M Performance:

+110.68%

1Y Performance:

+510.85%

1-Day Range:

$11.38

$13.74

1-Week Range:

$11.38

$14.37

52-Week Range:

$1.39

$15.88

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name

Sellas Life Sciences Group Inc

Sector

Healthcare (1069)

Industry

Biotechnology (595)

Phone

(646) 200-5278

Address

7 TIMES SQUARE, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

SLS's Discussions on Twitter

Compare SLS vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLS Sellas Life Sciences Group Inc	11.54	2.33B	0	-29.46M	-28.17M	-0.2283
VRTX Vertex Pharmaceuticals Inc	515.44	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	781.49	80.46B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.39	61.58B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	143.97	57.48B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.77	43.68B	742.00K	-1.37B	-1.07B	-7.0731

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-21-21	Initiated	Cantor Fitzgerald	Overweight
Nov-01-18	Initiated	Oppenheimer	Outperform
Apr-02-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Upgrade	Maxim Group	Hold → Buy

Sellas Life Sciences Group Inc Stock (SLS) Latest News

04:03 AM

SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Stocktwits

04:03 AM

03:00 AM

SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas - Stocktwits

03:00 AM

Sep 11, 2026

SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - Stocktwits

Sep 11, 2026

SLS Stock Rises Overnight: Why Retail Traders Prefer Sellas Over IBRX, ONDS, PYPL As Most Bullish Pick - Stocktwits

Sep 11, 2026

SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits

Sep 11, 2026

SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits

Sep 11, 2026

SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits

Sep 11, 2026

SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY - Stocktwits

Sep 11, 2026

SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits

Sep 11, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Sciences Group, Inc. (SLS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Sep 11, 2026

Life Sciences Companies Present Live at the September 17 Virtual Investor Forum - Yahoo Finance

Sep 11, 2026

10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga

Sep 11, 2026

Sep 10, 2026

SLS Stock Hits 4-Year High: BlackRock Stake Boost Fuels Buzz Around Looming AML Trial Readout - Stocktwits

Sep 10, 2026